Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.115 −25.8% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 0.990 −3.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.260 −1.9% GAL 0.400 +0.0% LIB 0.790 −13.2% SMY 0.275 +17.0% S 0.115 −25.8% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 0.990 −3.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.260 −1.9% GAL 0.400 +0.0% LIB 0.790 −13.2% SMY 0.275 +17.0%
Production / Operations

Promino Resumes Trading and Achieves Record Sales Growth Through October 2025

By The Northwire Desk — AI Analysis Dec 02, 2025 · 10:36 MUSL · 0.05 Promino Nutritional Sciences Inc
MUSL · Price

Executive Summary

  • Promino Nutritional Sciences Inc. resumed trading on the Canadian Securities Exchange after a halt since May 8, 2025.
  • FY 2025 revenue to Oct 31 reached $1.88 M (523% YoY growth), delivering positive gross profit margins.
  • The company announced a new CFO, highlighted strong Amazon sales (>$1 M YTD), expanded retail presence to 8,000+ stores, and launched a royalty‑free amino acid blend expected to cut operating expenses by $550k in FY 2026; it also indicated plans to seek additional financing.

Key Details

  • Trading Halt Lifted: Effective today (Dec 2, 2025) following filing of audited 2024 financials, MD&A, officer certifications, and interim reports for fiscal 2025.
  • Executive Appointment: Moira Ong appointed Chief Financial Officer; brings senior finance experience with CSE‑ and NASDAQ‑listed companies.
  • Revenue Growth: FY 2025 revenue to Oct 31 = $1.88 M vs. $0.289 M in calendar 2024 (523% increase). Cost of revenues $1.2 M, resulting in positive gross profit margins.
  • Amazon Performance: “Rejuvenate Muscle Health™” surpassed $1 M in Amazon.com sales YTD; >23,000 units sold since Jan 2025; ranks in Top 50 Protein Drinks category with positive margins.
  • Retail Expansion: Added 4,600 new U.S. pharmacy doors in July 2025; total North American store count now exceeds 8,000 locations.
  • Product Innovation: Launched a royalty‑free amino acid blend, projected to reduce annual operating expenses by >$550k starting FY 2026.
  • Financing Outlook: Company plans to seek additional capital (equity, debentures, or loans) to fund production needs for the remainder of 2025 and through 2026.
  • CEO Commentary: Vito Sanzone highlighted turnaround progress, revenue growth, e‑commerce and retail traction, and confidence in continued strong growth into 2026.

Notable Quotes

“To our loyal shareholders — thank you for your patience and belief in Promino during this extended pause… Revenue is growing and both e‑commerce and retail channels are demonstrating meaningful traction…” – Vito Sanzone, CEO

“The foundation we have built over the past year… gives us confidence that we will see continued strong growth through 2026.” – Vito Sanzone, CEO

Read the original news release →

More from Promino Nutritional Sciences Inc

Jun 30, 2026 · 18:46

Former CEO lawsuit adds minor legal friction to a company battling severe liquidity constraints and inventory depletion.

Regulatory Jun 18, 2026 · 06:01

Promino Expands U.S. NCAA Athlete Platform with Multi-Sport NIL Agreement with Every True Tiger

Financings Jun 09, 2026 · 06:01

Promino Launches Muscle Health Research Initiative Targeting GLP-1 Weight Management Market

Other Jun 05, 2026 · 22:04

Promino Announces Settlements and Amendments of Convertible Debentures

Financings Jun 04, 2026 · 06:01

Promino Nutritional Sciences Inc.

M&A / Property Jun 02, 2026 · 06:01

Promino(TM) Delivered to Stanley Cup Final Locker Room as Ambassador Jack Eichel Competes for Championship

M&A / Property